PROMOMED's Board of Directors will consider paying the first dividends in the Company's history.

April 15, 2026, Moscow – PJSC PROMOMED (MOEX: PRMD) (formerly "PROMOMED", the "Company" and, together with its subsidiaries– the "Group") informs that the CEO of PROMMED plans to recommend to the Board of Directors Committee on Strategy and Sustainable Development to consider the possibility of paying dividends.

In accordance with the Dividend Policy, the recommendation takes into account the Group's debt burden: the ratio of Net Debt[1] / adjusted EBITDA LTM[2] at the end of the reporting period (hereinafter referred to as the "Ratio").

The target dividend payment depends on the value of the Ratio according to the following criteria:
below / equal to 1 – at least 50% of the expected net profit[3]
above 1 – below / equal to 2 – at least 25% of the expected net profit
above 2 – below / equal to 2.5 – at least 15% of the expected net profit
Above 2.5, the issue of paying dividends is decided by the Board of Directors.

Based on the figures in the management reports, the CEO will propose allocating at least 35% of adjusted net profit under IFRS for 2025 to dividends.

Alexander Yefremov, CEO of PJSC PROMOMED, commented:

"PROMOMED has demonstrated record growth rates of key operational and financial indicators for its sector over the past year and a half. These achievements should naturally lead to the creation of additional value for the Company's shareholders.

We have carefully approached maintaining a balance between maintaining a stable financial position, investing in further business growth and dividend payments.

Adhering to the current dividend policy, taking into account the preliminary financial results for 2025, I am pleased to announce that I plan to recommend to the Board of Directors committee to consider the possibility of distributing the first dividends since the IPO."

The Company notes that the recommendations of the Board of Directors regarding dividends may differ from those of the CEO. The Company will additionally inform the investment community about the decisions of the Board of Directors regarding the parameters of possible payments in accordance with the procedure established by law. The final decision on the payment/non-payment of dividends is made by the General Meeting of Shareholders of the Company.

The Company also recalls the publication of financial results in accordance with IFRS standards for the 12 months of 2025 on April 20, 2026 and the holding of the annual Investor Day on April 21, 2026.

About the Company

PROMOMED is a leading innovative biopharmaceutical company with significant growth potential in promising segments of the pharmaceutical market.

The company's structure includes its own unique world-class R&D center and a high—tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company develops a diversified portfolio of more than 360 medicines in the top 10 segments of the pharmaceutical market. The Company's portfolio includes blockbuster drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the Company produces drugs for the treatment of diseases in various therapeutic areas: endocrinology, oncology, neurology, autoimmune diseases, infection control, acute and chronic pain, and others. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the Company is an active participant in the system of ensuring national drug safety and import independence of the country.

Contacts

For investors

For the media

ir@promomed.pro

pr@promomed.pro

Statement of limitation of liability

This message and the information contained therein are not:

an offer to purchase any securities,
an invitation to make offers for the purchase of any securities,
as part of such offers or invitations,
securities advertising in the Russian Federation or other jurisdictions,
an offer to purchase medicines,
advertising of medicines,
by encouraging or recommending transactions,
it is also not subject to interpretation as such.

Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.

Neither this announcement nor any part of it should serve as a basis for making any investment decisions and/or decisions on the use of any medicines.

The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the securities market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the only source of information when making an investment decision.

Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page. https://e-disclosure.ru/portal/company.aspx?id=38533 .

The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions contained in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). An indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.

The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.

The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.

[1] Net debt is an indicator of net debt, the calculation procedure of which is equal to the total amount owed on loans, borrowings and lease obligations, net of cash and cash equivalents, as well as short–term bank deposits at each reporting date.

[2] Adjusted EBITDA LTM (abbreviated EBITDA LTM) is an adjusted EBITDA indicator, a management indicator determined on an accrual basis over the past 12 calendar months, the calculation procedure and values of which are disclosed by the Company in the consolidated financial statements in accordance with IFRS.

[3] Adjusted net profit is the net profit for the period adjusted for the amount of capitalized expenses in respect of fixed assets and IA (payments in connection with the acquisition, creation, modernization, reconstruction and preparation for use of fixed assets and payments in connection with the acquisition and creation of intangible assets) and depreciation on capitalized expenses in respect of fixed assets funds and NMA.